
President @NAIconsulting. Helping businesses across healthcare define/implement strategies to win in dynamic markets.
St Louis, MO
Joined January 2016
- Tweets5.7K
- Following466
- Followers1.5K
- Likes314
Pinned Tweet
Market-driven healthcare is the future. My new book out today-"Bringing Value to Healthcare" youtu.be/L0ypIF5Mf8s
Manufacturers need to do more than generate evidence and prove value to the decision-makers shaping access and adoption. In my latest column, I explore how to build a compelling narrative for payers and IDNs.
Read more: nai-consulting.com/from-evid…
24
FDA approval doesn’t guarantee market access. Manufacturers need evidence that demonstrates differentiated clinical and economic value to payers, IDNs and other decision-makers.
Read more in my latest column: nai-consulting.com/getting-t…
149
Market access cannot remain a Phase 4 activity in pharmaceutical development. It needs to move closer to the beginning of R&D, informing which assets companies develop, what evidence they generate and where they invest.
Read more: nai-consulting.com/what-the-…
1
45
Continuity of care is a design failure of today's healthcare business model – not an operational inconvenience. Hospitals don't need more band-aids. They need a model where accountability follows the patient, not the shift.
My latest: nai-consulting.com/the-probl…
1
31
Sen. Bill Cassidy's 340B proposal deserves serious consideration. But the bigger question is why programs like 340B have become financially indispensable. We cannot keep treating the symptoms; we must address the underlying payment model. nai-consulting.com/what-sena…
45
Healthcare leaders no longer need to diagnose the problem – they need to execute change. In my latest column, I outline a framework for transformation built on a clear case for action, a concrete vision and the participation needed to make it happen. nai-consulting.com/beyond-di…
29
Healthcare has reached another inflection point. We've spent decades making incremental adjustments, yet costs continue to rise and dissatisfaction continues to grow.
My latest: nai-consulting.com/why-chang…
22
The @WaysandMeansGOP hearing underscored growing frustration with rising healthcare costs and limited evidence of measurable value. Organizations that can demonstrate both clinical and economic value will be best positioned for the future. nai-consulting.com/healthcar…
18
The recent hearing on hospital prices sent a clear signal: bipartisan patience with the current HCD model is wearing thin. Rising costs, consolidation and weak value transparency are now central questions in D.C. Incremental reform is no longer enough. nai-consulting.com/hospital-…
1
24
Pharma companies that continue to rely on legacy R&D and commercialization approaches will find it increasingly difficult to achieve approval and access on terms that support sustainable value. nai-consulting.com/why-the-o…
19
A $300B patent cliff is reshaping pharma competition, value and decision-making. As exclusivity expires, new value benchmarks compress pricing power and raise the bar for differentiation. Evidence must drive pricing, access and long-term viability.
nai-consulting.com/the-capab…
28
Big pharma cut 22,000+ jobs in 2025 as a $300B patent cliff looms. Periodic restructuring is not unusual, but the scale & simultaneity of these layoffs reveals a deeper industry shift and why evidence has become the central determinant of value.
Read more:bit.ly/4vjNk9Z
24
Vinay Prasad’s departure from the @US_FDA has renewed debate about balancing scientific rigor with timely patient access. This moment should not be viewed as a departure from scientific standards, but as an opportunity to refine them. bit.ly/480wbYP
18
.@Pharmacy_Times: The FDA’s move to expand RWE in clinical trials is an important step forward. Raising the evidentiary bar won’t stifle innovation—it ties price to value and helps ensure the U.S. continues to lead in both innovation and accountability. bit.ly/4rAB8zH
1
39
AI is rapidly becoming embedded across the pharmaceutical industry, but until organizations become more disciplined about defining the questions they need answered, even the most sophisticated AI capabilities will underperform.
Read More: bit.ly/49u7vI6
25
Cost pressure, access demands and accountability expectations are accelerating disruption across HCD and insurance. As 2026 approaches, shrinking fee-for-service viability and rising consumer expectations mean incremental adjustments will not be enough. bit.ly/4j8otjY
22
Policy pressure is reshaping the pharma landscape, and 2026 will require sharper evidence and clearer value communication to stay competitive. Our 2026 Global Pharma Outlook breaks down the key opportunities and challenges ahead.
Read more:
bit.ly/4aYMvf3
32
A 43-day shutdown over temporary ACA subsidies revealed the bigger issue: a system with misaligned incentives. Leaders need to shift from managing crises to designing a system anchored in accountability, competition and improving care at affordable prices. bit.ly/3K81mZK
58
Following @Pfizer & @AstraZeneca’s new deals with the Trump Admin, TrumpRx.gov marks a significant shift—elevating DTC pricing to a national priority and challenging pharma’s opaque model to restore a rational link between cost and value. bit.ly/3WBPXnG
46
The number of osteoporosis bone fractures is expected to increase by 68% from 1.9 million (2018) to 3.2 million in 2040, impacting patient quality of life and healthcare costs. Ask your doctor about screenings and prevention.
@Amgen @bonehealthBHOF @HealthyWomen
1
27
